Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’ Read more →

SK pens $315M pact with fellow South Korean company for Parkinson’s prospect Read more →

Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech Read more →